Gold prices steady ahead of Fed decision; weekly weakness noted
LONDON - Avacta Therapeutics (AIM:AVCT), a developer of peptide drug conjugates for cancer treatment, has postponed the release of its preliminary results for the year ended December 31, 2024. The new date for the announcement is set for June 4, 2025. The delay is due to the auditors requiring additional time to complete their work, particularly related to the disposal of Launch Diagnostics, which was finalized after the end of the reporting period.
The company, which focuses on delivering anti-tumor payloads directly to tumors, was initially scheduled to publish its results on May 29, 2025. However, the auditors have been unable to finalize the necessary audit work by this date. Avacta was informed of this delay on May 23, 2025.
Avacta has confirmed that this postponement does not affect the company’s financial position or its cash runway. The announcement was made to keep shareholders and potential investors informed of the change in schedule.
In conjunction with the release of the preliminary results, Christina Coughlin, Chief Executive Officer, and Brian Hahn, Chief Financial Officer, will present a live briefing via Investor Meet Company at 11:00 BST on June 4, 2025. The event is open to all current and prospective shareholders. Interested parties can sign up for the event for free and add Avacta Group PLC to their meeting schedule through the Investor Meet Company platform.
Investors who have already followed Avacta on Investor Meet Company will be automatically invited to the presentation. Additionally, participants are encouraged to submit questions before the event via the Investor Meet Company dashboard until 09:00 BST on the day of the presentation or during the live event itself.
Following the presentation, the company will post the results on its website for broader accessibility. This update is strictly based on a press release statement from Avacta Group plc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.